Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology
- PMID: 10560360
- PMCID: PMC1023076
- DOI: 10.1136/jcp.52.5.376
Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology
Abstract
Aims: To compare the efficacy of and tolerance to oral fluconazole and intraconazole in preventing fungal infection in neutropenic patients with haematological malignancies.
Patients: 213 consecutive, afebrile adult patients treated with or without autologous stem cell transplantation for haematological malignancies.
Methods: A randomised, double blind, single centre study. Patients were randomly assigned to receive fluconazole 50 mg or itraconazole 100 mg, both twice daily in identical capsules. An intention to treat analysis was performed on 202 patients, 101 in each group.
Results: Microbiologically documented systemic fungal infections occurred in four patients in each group. Clinical fungal infection was thought to be present in seven recipients of fluconazole and four of itraconazole. In all 202 patients, 29 proceeded to intravenous amphotericin (amphotericin B), 16 in the fluconazole group and 13 in the itraconazole group. Superficial fungal infection was seen only in three non-compliant patients in the fluconazole group. All these infections were oral. No major differences were noted in the isolates of fungi in mouth washes and fecal samples. Overall mortality was 8.9% (18 deaths; seven in the fluconazole group, 11 in the itraconazole group). Mortality from microbiologically and clinically documented fungal infection was 4.5% (nine deaths; three in the fluconazole group, six in the itraconazole group). Median time to suspected or proven fungal infection was 16 days in both groups. None of these comparisons reached statistical significance (p < 0.05). No major clinical toxicity was noted and compliance was excellent.
Conclusions: In neutropenic patients treated for haematological malignancies with or without autologous stem cell transplantation, fluconazole and itraconazole in low doses result in a similar low frequency of fungal disease. Fluconazole may be the preferable drug because of the smaller number of capsules and lack of need for timing relative to meals.
Similar articles
-
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.J Antimicrob Chemother. 2006 Feb;57(2):317-25. doi: 10.1093/jac/dki440. Epub 2005 Dec 8. J Antimicrob Chemother. 2006. PMID: 16339606 Clinical Trial.
-
A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.Br J Haematol. 1999 Jun;105(4):901-11. doi: 10.1046/j.1365-2141.1999.01465.x. Br J Haematol. 1999. PMID: 10554799 Clinical Trial.
-
Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.Br J Haematol. 2005 Oct;131(1):22-8. doi: 10.1111/j.1365-2141.2005.05727.x. Br J Haematol. 2005. PMID: 16173959
-
Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i23-i32. doi: 10.1093/jac/dki221. J Antimicrob Chemother. 2005. PMID: 16120631 Review.
-
Antifungal prophylaxis with itraconazole oral solution in neutropenic patients.Mycoses. 1999;42 Suppl 2:121-4. Mycoses. 1999. PMID: 10865918 Review.
Cited by
-
Current management of fungal infections.Drugs. 2001;61 Suppl 1:13-25. doi: 10.2165/00003495-200161001-00002. Drugs. 2001. PMID: 11219547 Review.
-
Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.Haematologica. 2009 Jan;94(1):113-22. doi: 10.3324/haematol.11665. Epub 2008 Dec 9. Haematologica. 2009. PMID: 19066334 Free PMC article.
-
Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.JAMA Netw Open. 2020 Oct 1;3(10):e2017652. doi: 10.1001/jamanetworkopen.2020.17652. JAMA Netw Open. 2020. PMID: 33030550 Free PMC article.
-
Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials.Med Oncol. 2010 Dec;27(4):1082-8. doi: 10.1007/s12032-009-9339-0. Epub 2009 Oct 30. Med Oncol. 2010. PMID: 19876778
-
Clinical experience with itraconazole in systemic fungal infections.Drugs. 2001;61 Suppl 1:39-47. doi: 10.2165/00003495-200161001-00004. Drugs. 2001. PMID: 11219549 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical